Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016
Published Jun 08, 2016
94 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
- The report reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) therapeutics and enlists all their major and minor projects
- The report assesses Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeu

  
Source:
Document ID
GMDHC8183IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview91
Therapeutics Development101
  Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview101
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics under Development by Companies111
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Products under Development by Companies152
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Companies Involved in Therapeutics Development1712
  Adverum Biotechnologies, Inc.171
  Arrowhead Pharmaceuticals, Inc.181
  BioCryst Pharmaceuticals, Inc.191
  Cevec Pharmaceuticals GmbH201
  CSL Limited211
  Global Blood Therapeutics, Inc.221
  iBio, Inc.231
  Ionis Pharmaceuticals, Inc.241
  Pharming Group N.V.251
  ProMetic Life Sciences Inc.261
  Ra Pharmaceuticals, Inc.271
  Shire Plc281
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Assessment299
  Assessment by Monotherapy Products291
  Assessment by Target302
  Assessment by Mechanism of Action322
  Assessment by Route of Administration342
  Assessment by Molecule Type362
Drug Profiles3830
  ANN-002 - Drug Profile381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  ARCF-12 - Drug Profile391
    Product Description391
    Mechanism of Action391
    R&D Progress391
  avoralstat - Drug Profile401
    Product Description401
    Mechanism of Action401
    R&D Progress401
  BCX-7353 - Drug Profile411
    Product Description411
    Mechanism of Action411
    R&D Progress411
  BEL-0215 - Drug Profile421
    Product Description421
    Mechanism of Action421
    R&D Progress421
  C1 esterase inhibitor (human) - Drug Profile431
    Product Description431
    Mechanism of Action431
    R&D Progress433
  C1 esterase inhibitor (human) - Drug Profile461
    Product Description461
    Mechanism of Action461
    R&D Progress462
  C1 esterase inhibitor (human) - Drug Profile481
    Product Description481
    Mechanism of Action481
    R&D Progress481
  C1 esterase inhibitor (recombinant) - Drug Profile491
    Product Description491
    Mechanism of Action491
    R&D Progress495
  C1 esterase inhibitor (recombinant) - Drug Profile541
    Product Description541
    Mechanism of Action541
    R&D Progress541
  CSL-312 - Drug Profile551
    Product Description551
    Mechanism of Action551
    R&D Progress551
  GBT-18713 - Drug Profile561
    Product Description561
    Mechanism of Action561
    R&D Progress561
  icatibant acetate - Drug Profile571
    Product Description571
    Mechanism of Action571
    R&D Progress572
  IONIS-PKKRx - Drug Profile591
    Product Description591
    Mechanism of Action591
    R&D Progress591
  lanadelumab - Drug Profile601
    Product Description601
    Mechanism of Action601
    R&D Progress602
  Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile621
    Product Description621
    Mechanism of Action621
    R&D Progress621
  SHP-623 - Drug Profile631
    Product Description631
    Mechanism of Action631
    R&D Progress631
  Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile641
    Product Description641
    Mechanism of Action641
    R&D Progress642
  Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile661
    Product Description661
    Mechanism of Action661
    R&D Progress661
  Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema - Drug Profile671
    Product Description671
    Mechanism of Action671
    R&D Progress671
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Recent Pipeline Updates6818
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Product Development Milestones867
  Featured News &Press Releases861
    May 19, 2016: KalVista Pharmaceuticals to Support Global Conference Focused on Hereditary Angioedema861
    Apr 07, 2016: Pharming Announces Adoption By The European Commission Of The CHMP Recommendation To Change The Terms Of The Marketing Authorisation For Ruconest861
    Mar 23, 2016: CINRYZE (C1 inhibitor [human]) now available in Canada871
    Feb 26, 2016: Pharming Announces Positive CHMP Opinion To Change The Terms Of The Marketing Authorisation For Ruconest871
    Feb 09, 2016: Pharming And Cytobioteck Announce Extension Of Distribution Agreement For Ruconest881
    Feb 08, 2016: BioCryst Announces Results From OPuS-2881
    Jan 06, 2016: Pharming Announces Completion Of Patient Enrolment In Clinical Study Of Ruconest For Prophylaxis Of Hereditary Angioedema891
    Dec 21, 2015: Pharming And Hyupjin Announce Receipt Of The South Korean Marketing Authorisation For Ruconest901
    Dec 07, 2015: European Medicines Agency Reaffirms Important Health Benefits and Safety of RUCONEST for Patients With Hereditary Angio-edema901
    Nov 09, 2015: Dyax Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology Annual Meeting912
Appendix932
  Methodology931
  Coverage931
  Secondary Research931
  Primary Research931
  Expert Panel Validation931
  Contact Us931
  Disclaimer941

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hereditary-Angioedema-HAE-C1-Esterase-Inhibitor-C1-INH-Deficiency-Pipeline-Review-H1-2016-2088-15915>
  
APA:
Global Markets Direct - Market Research. (2016). Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hereditary-Angioedema-HAE-C1-Esterase-Inhibitor-C1-INH-Deficiency-Pipeline-Review-H1-2016-2088-15915>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.